Myospaz

# Myospaz ## Overview Myospaz is a brand name. Its composition can vary, but commonly it refers to a combination of **Paracetamol (Acetaminophen)** and **Tizanidine**. - **Classification**: Analgesic (Paracetamol) & Centrally Acting Skeletal Muscle Relaxant (Tizanidine). - **Mechanism**: Paracetamol provides analgesia by inhibiting prostaglandin synthesis centrally. Tizanidine is an alpha-2 adrenergic agonist that reduces muscle spasticity by increasing presynaptic inhibition of motor neurons. ## Primary Indications 1. **Acute Painful Musculoskeletal Conditions**: Relief of muscle spasm and associated pain. 2. **Muscle Spasticity**: While Tizanidine monotherapy is used for spasticity, the combination is for spasms with pain. ## Adult Dosing ### Standard Dosing **Acute Painful Musculoskeletal Conditions** - **Dose**: Typically **Paracetamol 325-500 mg + Tizanidine 2 mg**. Refer to specific product labeling. - **Frequency**: **Twice to three times daily (BID-TID)**. - **Route**: Oral. - **Duration**: Short-term use, generally up to **10-14 days**. ### Dose Adjustments - **Renal Impairment**: - **Tizanidine**: Reduce dose in CrCl < 25 mL/min (e.g., start at **2 mg once daily**, titrate slowly). - **Paracetamol**: No specific adjustment needed for mild-moderate impairment. Avoid/use with caution in severe renal impairment if high doses are required. - **Hepatic Impairment**: - **Tizanidine**: Contraindicated in severe hepatic impairment. Use with caution in mild-moderate. - **Paracetamol**: Use with extreme caution or avoid in severe hepatic impairment; adjust dose or extend interval. Max daily dose of **2000 mg** in chronic liver disease. - **Elderly Patients**: - Start with lower doses and titrate slowly due to increased sensitivity to Tizanidine's adverse effects (sedation, hypotension). Monitor renal/hepatic function. ## Pediatric Dosing **Myospaz (Paracetamol + Tizanidine combination) is generally NOT recommended for pediatric patients.** - **Tizanidine**: Not approved for pediatric use. Safety and efficacy in children have not been established. - **Specific Age Groups**: Due to the Tizanidine component, this combination product should not be used in neonates, infants, children, or adolescents (under 18 years of age). - **Special Notes**: If pain relief is needed for a child, **Paracetamol monotherapy** in appropriate pediatric formulations and dosing is recommended. Consult a pediatrician for appropriate management. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Paracetamol, Tizanidine, or any excipients. - **Absolute**: Concomitant use with strong CYP1A2 inhibitors (e.g., Fluvoxamine, Ciprofloxacin) due to severe hypotension risk with Tizanidine. - **Absolute**: Severe hepatic impairment (due to both components). - **Absolute**: Severe renal impairment (Tizanidine). ### Common Adverse Effects - **Very Common (>10%)**: Drowsiness/Sedation, dry mouth, dizziness, asthenia (Tizanidine). - **Common (1-10%)**: Nausea, abdominal pain (Paracetamol); Hypotension, bradycardia, fatigue (Tizanidine). - **Serious but Rare**: - **Paracetamol**: Acute liver failure (especially with overdose), serious skin reactions (SJS, TEN). - **Tizanidine**: Severe hypotension, liver injury, hallucinations, QT prolongation, rebound hypertension upon abrupt discontinuation. ### Key Drug Interactions - **Strong CYP1A2 Inhibitors (e.g., Fluvoxamine, Ciprofloxacin)**: Markedly increases Tizanidine levels, leading to severe hypotension and CNS depression. **Concomitant use is contraindicated.** - **CNS Depressants (e.g., Alcohol, Opioids, Benzodiazepines, Antihistamines)**: Additive sedative effects; increases risk of respiratory depression. **Avoid concomitant use.** - **Oral Contraceptives**: May increase Tizanidine levels. Monitor for increased adverse effects. - **Antihypertensives**: Increased risk of hypotension and bradycardia. Monitor blood pressure closely. - **Other Hepatotoxic Drugs**: Increased risk of liver injury with Paracetamol. ## Monitoring & Follow-up - **Before Treatment**: - Baseline Liver Function Tests (LFTs) for patients with pre-existing hepatic impairment or prolonged use history. - Baseline Blood Pressure (BP) and Heart Rate (HR). - **During Treatment**: - Monitor BP and HR regularly, especially after dose initiation or titration (Tizanidine). - Monitor for signs of excessive sedation, dizziness, or weakness. - If prolonged use or high doses, consider periodic LFTs. - **Clinical Signs**: Watch for yellowing of skin/eyes, dark urine, severe abdominal pain (liver injury); severe dizziness, fainting (hypotension); profound drowsiness. ## Clinical Pearls - 💡 **Sedation Risk**: Counsel patients about significant drowsiness and dizziness. Advise against driving or operating heavy machinery. - 💡 **Alcohol Avoidance**: Advise strict avoidance of alcohol due to increased sedative and potential hepatotoxic effects. - 💡 **Tapering Tizanidine**: Do not abruptly discontinue Tizanidine after prolonged use or high doses to avoid rebound hypertension, tachycardia, and hypertonia. Taper slowly. - 💡 **Overdose**: Emphasize strict adherence to dosing limits due to Paracetamol's narrow therapeutic index and hepatotoxicity risk. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.